All In Biotech

Drug Trial Radar · NCT07539311

Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

May 11, 2026

Primary completion

Sep 2028

Study completion Nov 2028

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Apr 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study will be conducted in different countries around the world with up to about 160 participants. The purpose of this study is to evaluate how well Rina-S works against GI cancers. The medication in this study is Rina-S monotherapy (by itself; no other cancer treatments). All participants will receive active drug; no one will be given placebo. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective. The duration of the study will be different for every participant, but an average study duration of 22 months is expected for participants. This will include a treatment period (expected to last an average of 12 months), plus data collection periods before and after treatment. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of an individual cycle is 21 days). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.

Conditions

  • Gastrointestinal Cancers

Interventions

  • Rina-SBiological

    Intravenous (IV) administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 22 months

Locations

28 sites in 11 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology, Santa Monica

    Santa Monica, California · Recruiting

  • University of Colorado Hospitak Anschutz

    Aurora, Colorado · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Greco-Hainsworth Center for Research

    Nashville, Tennessee · Recruiting

  • START San Antonio

    San Antonio, Texas · Recruiting

  • Cancer Research SA Pty Ltd

    Adelaide, Australia · Recruiting

  • GenesisCare St Leonards

    Saint Leonards, New South Wales, Australia · Recruiting

  • St John of God Subiaco Hospital

    Subiaco, Western Australia, Australia · Recruiting

  • Cliniques Universitaires Saint-Luc | Cliniques Universitaires Saint-Luc|Head and Neck tumors, Route 407 | Cliniques Universitaires Saint-Luc|Hematology

    Brussels, Belgium · Recruiting

  • Centre Hospitalier de l'Ardenne|Service Oncologie

    Libramont, Belgium · Recruiting

  • Hôpital Saint-Antoine Onco Med

    Paris, France · Recruiting

  • CHU Brest Cavale Blanche

    Brest, Brittany (Bretagne), France · Recruiting

  • Institut Régional du Cancer de Montpellier

    Montpellier, Herault, France · Recruiting

  • Hôpital Européen Georges Pompidou

    Paris, Paris, France · Recruiting

  • Centre Leon Berard

    Lyon, Rhone, France · Recruiting

  • Asklepios Klinik Altona

    Hamburg, Free and Hanseatic City of Hamburg, Germany · Recruiting

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan · Recruiting

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan · Recruiting

  • The University of Osaka Hospital

    Suita, Osaka, Japan · Recruiting

  • Cancer Institute Hospital of JFCR

    Kōtoku, Tokyo-To, Japan · Recruiting

  • Amsterdam UMC, Locatie VUMC|Hematology

    Amsterdam, Netherlands · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

  • University College London Hospitals

    London, Greater London, United Kingdom · Recruiting

  • Hammersmith Hospital

    London, Greater London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.